AKB-6899

• Description :

  AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects[1].

• Product Name Alternative :

  KPT-8602 (Z-isomer), CL29926; (±)-Imazamox, MKC242 (free base), MKC250

• UNSPSC :

  12352005

• Target :

  HIF/HIF Prolyl-Hydroxylase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/akb-6899.html

• Concentration :

  10mM

• Purity :

  99.95

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(CNC(C1=NC=C(C=C1O)C2=CC=CC(F)=C2)=O)O

• Molecular Formula :

  C14H11FN2O4

• Molecular Weight :

  290.25

• References & Citations :

  [1]Julie M Roda, et al. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol. 2012 Sep 15;189 (6) :3168-77.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1007377-55-0]